Skip to content
DataLookout
Menu

KMDNCT06496750

Ketamine for Methamphetamine Use Disorder

StatusCompleted
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 20 versions: 18 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial completed
    • Study completion date changed from estimate of Oct 2026 to Oct 15, 2026
  2. Notable Eligibility criteria expanded, about 9 words
    • Primary completion date changed from estimate of Aug 2026 to Sep 6, 2026
    • Secondary endpoints: details revised at 1 of 6 entries
  3. Minor Enrollment closed, study ongoing
    • Primary completion date: Aug 18, 2026 to Aug 2026
    • Study completion date: Oct 15, 2026 to Oct 2026
    • Site details revised at 5 of 5 sites
    v17
  4. Minor Study sites: 4 to 5v16
  5. Minor Site contacts updated at 1 of 4 sitesv15
Show 12 earlier versionsHide 12 earlier versions
  1. Minor Site details revised at 1 of 4 sitesv14
  2. Minor Primary completion date: Feb 1, 2027 to Aug 18, 2026
    • Study completion date: Apr 1, 2027 to Oct 15, 2026
    • Site contacts updated at 1 of 4 sites
    v13
  3. Minor Site contacts updated at 1 of 4 sitesv12
  4. Minor Site details revised at 1 of 4 sitesv11
  5. Minor Site details revised at 3 of 4 sitesv10
  6. Minor Study description revisedv9
  7. Minor Study sites: 1 to 4v8
  8. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 3, 2024 to Sep 11, 2024
    • Site details revised
    v7
  9. Notable Start date: Sep 3, 2024 to Oct 3, 2024v6
  10. Minor Site contact updatedv5
  11. Notable Start date: Aug 1, 2024 to Sep 3, 2024v4
  12. Notable Eligibility criteria expanded, about 5 wordsv3
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Treatment Response
Timeframe: 2 weeks

Secondary (6)

Non-serious adverse outcomes associated with IV ketamine treatment for methamphetamine use
Adherence to treatment
Total abstinence
Abstinence from methamphetamine use
Differences in methamphetamine-negative urine samples from Weeks 1 to 6 and between ketamine and midazolam arms.
Show 1 moreShow less
Differences in methamphetamine-negative urine samples from Weeks 1 and 2 versus Weeks 3 and 4.

Arms and interventions

KetamineExperimental

Participants will receive IV ketamine (0.50mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump at a constant rate over 40 minutes. IV ketamine will be administered 8 times over 6 weeks.

MidazolamActive comparator

Participants will receive IV midazolam (0.02mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump at a constant rate over 40 minutes. IV midazolam will be administered 8 times over 6 weeks.

Drugs: Ketamine Hydrochloride, Midazolam Hydrochloride

Sites

5 sites in 1 country